These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

237 related items for PubMed ID: 24749847

  • 1. Repeat treatment of acute hereditary angioedema attacks with open-label icatibant in the FAST-1 trial.
    Malbrán A, Riedl M, Ritchie B, Smith WB, Yang W, Banerji A, Hébert J, Gleich GJ, Hurewitz D, Jacobson KW, Bernstein JA, Khan DA, Kirkpatrick CH, Resnick D, Li H, Fernández Romero DS, Lumry W.
    Clin Exp Immunol; 2014 Aug; 177(2):544-53. PubMed ID: 24749847
    [Abstract] [Full Text] [Related]

  • 2. Repeat treatment with icatibant for multiple hereditary angioedema attacks: FAST-2 open-label study.
    Baş M, Greve J, Hoffmann TK, Reshef A, Aberer W, Maurer M, Kivity S, Farkas H, Floccard B, Arcoleo F, Martin L, Sitkauskiene B, Bouillet L, Schmid-Grendelmeier P, Li H, Zanichelli A.
    Allergy; 2013 Nov; 68(11):1452-9. PubMed ID: 24111645
    [Abstract] [Full Text] [Related]

  • 3. Icatibant for Multiple Hereditary Angioedema Attacks across the Controlled and Open-Label Extension Phases of FAST-3.
    Lumry WR, Farkas H, Moldovan D, Toubi E, Baptista J, Craig T, Riedl M.
    Int Arch Allergy Immunol; 2015 Nov; 168(1):44-55. PubMed ID: 26556097
    [Abstract] [Full Text] [Related]

  • 4. Randomized placebo-controlled trial of the bradykinin B₂ receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial.
    Lumry WR, Li HH, Levy RJ, Potter PC, Farkas H, Moldovan D, Riedl M, Li H, Craig T, Bloom BJ, Reshef A.
    Ann Allergy Asthma Immunol; 2011 Dec; 107(6):529-37. PubMed ID: 22123383
    [Abstract] [Full Text] [Related]

  • 5. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema.
    Cicardi M, Banerji A, Bracho F, Malbrán A, Rosenkranz B, Riedl M, Bork K, Lumry W, Aberer W, Bier H, Bas M, Greve J, Hoffmann TK, Farkas H, Reshef A, Ritchie B, Yang W, Grabbe J, Kivity S, Kreuz W, Levy RJ, Luger T, Obtulowicz K, Schmid-Grendelmeier P, Bull C, Sitkauskiene B, Smith WB, Toubi E, Werner S, Anné S, Björkander J, Bouillet L, Cillari E, Hurewitz D, Jacobson KW, Katelaris CH, Maurer M, Merk H, Bernstein JA, Feighery C, Floccard B, Gleich G, Hébert J, Kaatz M, Keith P, Kirkpatrick CH, Langton D, Martin L, Pichler C, Resnick D, Wombolt D, Fernández Romero DS, Zanichelli A, Arcoleo F, Knolle J, Kravec I, Dong L, Zimmermann J, Rosen K, Fan WT.
    N Engl J Med; 2010 Aug 05; 363(6):532-41. PubMed ID: 20818888
    [Abstract] [Full Text] [Related]

  • 6. Treatment of hereditary angioedema with icatibant: efficacy in clinical trials versus effectiveness in the real-world setting.
    Maurer M, Longhurst HJ, Fabien V, Li HH, Lumry WR.
    Allergy Asthma Proc; 2014 Aug 05; 35(5):377-81. PubMed ID: 25198193
    [Abstract] [Full Text] [Related]

  • 7. Treatment Effect and Safety of Icatibant in Pediatric Patients with Hereditary Angioedema.
    Farkas H, Reshef A, Aberer W, Caballero T, McCarthy L, Hao J, Nothaft W, Schranz J, Bernstein JA, Li HH.
    J Allergy Clin Immunol Pract; 2017 Aug 05; 5(6):1671-1678.e2. PubMed ID: 28601641
    [Abstract] [Full Text] [Related]

  • 8. Open-label, multicenter study of self-administered icatibant for attacks of hereditary angioedema.
    Aberer W, Maurer M, Reshef A, Longhurst H, Kivity S, Bygum A, Caballero T, Bloom B, Nair N, Malbrán A.
    Allergy; 2014 Mar 05; 69(3):305-14. PubMed ID: 24438203
    [Abstract] [Full Text] [Related]

  • 9. [EFFICACY, PHARMACOKINETICS, AND SAFETY OF ICATIBANT FOR THE TREATMENT OF JAPANESE PATIENTS WITH AN ACUTE ATTACK OF HEREDITARY ANGIOEDEMA: A PHASE 3 OPEN-LABEL STUDY].
    Hide M, Fukunaga A, Maehara J, Eto K, Hao J, Vardi M, Nomoto Y.
    Arerugi; 2018 Mar 05; 67(2):139-147. PubMed ID: 29553114
    [Abstract] [Full Text] [Related]

  • 10. Efficacy, pharmacokinetics, and safety of icatibant for the treatment of Japanese patients with an acute attack of hereditary angioedema: A phase 3 open-label study.
    Hide M, Fukunaga A, Maehara J, Eto K, Hao J, Vardi M, Nomoto Y.
    Allergol Int; 2020 Apr 05; 69(2):268-273. PubMed ID: 31672405
    [Abstract] [Full Text] [Related]

  • 11. Subcutaneous Icatibant for the Treatment of Hereditary Angioedema Attacks: Comparison of Home Self-Administration with Administration at a Medical Facility.
    Otani IM, Lumry WR, Hurwitz S, Li HH, Craig TJ, Holtzman NS, Iandoli MI, Tucker J, Riedl MA, Zuraw BL, Banerji A.
    J Allergy Clin Immunol Pract; 2017 Apr 05; 5(2):442-447.e1. PubMed ID: 27818136
    [Abstract] [Full Text] [Related]

  • 12. Comparing acquired angioedema with hereditary angioedema (types I/II): findings from the Icatibant Outcome Survey.
    Longhurst HJ, Zanichelli A, Caballero T, Bouillet L, Aberer W, Maurer M, Fain O, Fabien V, Andresen I, IOS Study Group.
    Clin Exp Immunol; 2017 Apr 05; 188(1):148-153. PubMed ID: 27936514
    [Abstract] [Full Text] [Related]

  • 13. Hereditary angioedema with normal C1 inhibitor in a French cohort: Clinical characteristics and response to treatment with icatibant.
    Bouillet L, Boccon-Gibod I, Launay D, Gompel A, Kanny G, Fabien V, Fain O, IOS Study Group.
    Immun Inflamm Dis; 2017 Mar 05; 5(1):29-36. PubMed ID: 28250922
    [Abstract] [Full Text] [Related]

  • 14. Icatibant, an inhibitor of bradykinin receptor 2, for hereditary angioedema attacks: prospective experimental single-cohort study.
    Campos RA, Valle SO, França AT, Cordeiro E, Serpa FS, Mello YF, Malheiros T, Toledo E, Mansour E, Fusaro G, Grumach AS.
    Sao Paulo Med J; 2014 Mar 05; 132(5):261-5. PubMed ID: 25054967
    [Abstract] [Full Text] [Related]

  • 15. Icatibant for the treatment of hereditary angioedema.
    Cole SW, Lundquist LM.
    Ann Pharmacother; 2013 Jan 05; 47(1):49-55. PubMed ID: 23249729
    [Abstract] [Full Text] [Related]

  • 16. Icatibant as acute treatment for hereditary angioedema in adults.
    Farkas H.
    Expert Rev Clin Pharmacol; 2016 Jun 05; 9(6):779-88. PubMed ID: 27123689
    [Abstract] [Full Text] [Related]

  • 17. Icatibant for hereditary angioedema.
    Gras J.
    Drugs Today (Barc); 2009 Dec 05; 45(12):855-64. PubMed ID: 20135020
    [Abstract] [Full Text] [Related]

  • 18. Safety and efficacy of icatibant self-administration for acute hereditary angioedema.
    Boccon-Gibod I, Bouillet L.
    Clin Exp Immunol; 2012 Jun 05; 168(3):303-7. PubMed ID: 22519593
    [Abstract] [Full Text] [Related]

  • 19. The Icatibant Outcome Survey: treatment of laryngeal angioedema attacks.
    Longhurst HJ, Aberer W, Bouillet L, Caballero T, Maurer M, Fabien V, Zanichelli A, IOS Study Group.
    Eur J Emerg Med; 2016 Jun 05; 23(3):224-7. PubMed ID: 27116379
    [Abstract] [Full Text] [Related]

  • 20. Management of hereditary angioedema in Japan: Focus on icatibant for the treatment of acute attacks.
    Hide M, Horiuchi T, Ohsawa I, Andresen I, Fukunaga A.
    Allergol Int; 2021 Jan 05; 70(1):45-54. PubMed ID: 32919903
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.